Ottimo Pharma, a Sandwich, UK-based private biotech company developing cancer therapies, emerged from stealth with funding from Medicxi and management team.
The amount of the deal was not disclosed.
The company intends to use the funds to expand operations and its R&D sector.
Co-founded in 2020 by Medicxi and Jonny Finlay, Ottimo Pharma is a biotechnology company focused on the development of cancer therapies for solid tumors. Its lead program, Jankistomig, is a PD1-VEGFR2 bi-functional antibody designed to target both immune checkpoint inhibition and angiogenesis in a single IgG therapy. By advancing this dual-pathway approach, the company aims to improve cancer treatment outcomes and reduce overall healthcare burden.
It also announced the appointments of David Epstein as Chair & Chief Executive Officer, Mehdi Shahidi as Head of Development & Chief Medical Officer, and James Sabry as Vice-Chair of the Board of Directors.
FinSMEs
28/10/2024